Investors might be looking at the stock's fall in recent years as a potential buying opportunity. Because of the potential to achieve strong returns, it makes sense that investors want to find companies benefiting from secular trends. Roku (ROKU 3.82%) fits the bill, but long-term shareholders haven't been rewarded. As of Aug. 22, this streaming stock trades an alarming 80% below its peak, even though it has climbed 27% in 2025. This huge dip might prompt investors to want to add the business to their portf ...

https://www.wsj.com/tech/inside-intels-tricky-dance-with-trump-c03f729c This copy is for your personal, non-commercial use only. Distribution and use of this material are governed byour Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contactDow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. ...

Shares of Nvidia are hovering near all-time highs. It's hard to believe that at one point this year, Nvidia (NVDA 1.65%) stock had plummeted by 30% and lost over $1 trillion in market value. Despite trading near all-time highs, some Wall Street analysts see even more upside ahead -- with price targets forecasting as much as 400% further gains. In other words, many investors think Nvidia stock is still undervalued. Let's explore the catalysts that could fuel Nvidia even higher, and detail why now may as good ...

Core Viewpoint - HUTCHMED announces the temporary leave of its CEO Dr. Weiguo Su due to health reasons, with CFO Johnny Cheng appointed as Acting CEO to ensure continuity in operations and strategy execution [1][2]. Company Leadership Changes - Dr. Weiguo Su, the Executive Director and CEO, is taking a leave of absence for health reasons, emphasizing the need to focus on his recovery [1][2]. - Johnny Cheng, currently the Executive Director and CFO, has been appointed as Acting CEO, effective immediately, while continuing his role as CFO [1][2]. Board Support and Confidence - The Board of Directors expresses full support for Dr. Su and confidence in Mr. Cheng's capabilities to manage the company during this interim period [2]. - The Board reassures stakeholders that all research, development, and commercial initiatives will remain on track despite the leadership change [2]. Company Overview - HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [3]. - The company has successfully marketed its first three medicines in China, with the first also approved in global markets including the US, Europe, and Japan [3].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased PubMatic, Inc. securities between February 27, 2025, and August 11, 2025, due to alleged misleading statements by the company regarding its business operations and revenue impacts from a significant demand side platform buyer [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that PubMatic made false and misleading statements about its business, failing to disclose a shift of clients from a top demand side platform buyer to a new platform, which resulted in reduced ad spend and revenue [5]. - Investors who purchased PubMatic securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 20, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Innovent Biologics has received FDA clearance for the IND application to initiate a global Phase 3 clinical trial of IBI363, a novel PD-1/IL-2α-bias bispecific antibody fusion protein, targeting immunotherapy-resistant squamous non-small cell lung cancer (NSCLC) [1][2][10] Group 1: Clinical Trial Details - The Phase 3 trial, named MarsLight-11, will enroll approximately 600 patients globally, including regions such as China, the U.S., Canada, the EU, the UK, and Japan [3] - The study will compare the efficacy and safety of IBI363 at a dosage of 3 mg/kg as monotherapy against docetaxel in patients with unresectable, locally advanced or metastatic squamous NSCLC who have shown disease progression after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy [3] - The primary endpoint of the trial is overall survival [3] Group 2: Regulatory Approvals and Designations - The IND clearance follows positive feedback from the FDA during the End-of-Phase 2 meeting, with major alignments reached on dose selection and study design [2] - IBI363 has received Fast Track Designation (FTD) from the FDA and Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA) for this indication [2] Group 3: Mechanism and Efficacy - IBI363 operates by simultaneously blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway, targeting tumor-specific T cells [9] - Preliminary trials have shown that IBI363 induces tumor remission in some patients and achieves disease stability in the majority, indicating durable anti-tumor activity [8] - Compared to traditional chemotherapy, IBI363 is expected to offer advantages in objective response rate (ORR) and progression-free survival (PFS) [8] Group 4: Broader Development Strategy - Innovent is advancing IBI363 into registrational studies, with ongoing pivotal trials in melanoma and plans for colorectal cancer [5][6] - Multiple Phase 1b/2 trials are evaluating IBI363 as both monotherapy and in combination therapies across various cancer types, including first-line NSCLC and platinum-resistant ovarian cancer [6] - The comprehensive development strategy aims to maximize the value of IBI363 and expand its potential in large global oncology markets [6] Group 5: Company Vision and Pipeline - Innovent's mission is to empower patients worldwide with affordable, high-quality biopharmaceuticals, and it aims to build a global premier biopharmaceutical leader [11] - The company has launched 16 products and has 2 new drug applications under regulatory review, alongside 4 assets in Phase III or pivotal clinical trials [12]

Core Insights - The article emphasizes the potential for investment in undervalued stocks that are mispriced by the market in August [1] Group 1 - The article suggests that investors should consider joining a platform that provides insights on undervalued stocks [1]

Amazon's flywheel is still accelerating Why Intuitive Surgical's runway keeps getting longer Intuitive posted a strong Q2, with revenue up 21% year over year to $2.44 billion and non‑GAAP diluted earnings per share (EPS) of $2.19 -- up 23%. Growth was broad-based across its different key sales drivers -- instruments, accessories, and systems placements. This momentum reflects rising procedure volume and continued adoption of the company's latest minimally invasive surgical platform: the da Vinci 5. The life ...

The Ten Titans already make up 38% of the S&P 500, but their share could grow if companies keep delivering on investor expectations. In early August 2018, Apple (AAPL 1.21%) became the first U.S. company to surpass $1 trillion in market cap. Fast forward seven years, and there are nine S&P 500 (^GSPC 1.52%) components with market caps over $1 trillion: the "Magnificent Seven" consisting of Nvidia (NVDA 1.65%), Microsoft (MSFT 0.56%), Apple, Amazon (AMZN 3.12%), Alphabet (GOOG 2.98%) (GOOGL 3.17%), Meta Plat ...

But is the analyst right to be so bearish on Tesla? Robotaxi progress is real -- but supervised Tesla began a small, invite-only robotaxi pilot in Austin this summer. Rides are geofenced and -- crucially -- still include an in-car supervisor. That's progress, but it is not unsupervised autonomy. This is an important distinction, because to live up to the stock's sky-high valuation, we're going to need fully unsupervised autonomous ride-sharing. Regulators had been watching even before the pilot launched. In ...